comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 16:26:10 - browse：52282

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： FDA greenlights medical device to combat bladder issues

WSS

Vivek Ramaswamy made waves in the debate, much as in biotech

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Anavex keeps shifting the goalposts in its clinical trials

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

NIH trials fail to test meaningful long Covid therapies, experts say

Can U.S. cancer drug shortages be fixed?

focus

comprehensive

explore

Activists slam private health insurers over coverage restrictions

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Can U.S. cancer drug shortages be fixed?

In age of alternative facts, a scholarly course on calling out crap

Wegovy’s successful heart trial raises vital question about weight loss

In Memoriam: Notable people who died in 2023

California store owner shot dead in dispute over displaying Pride flag: Police

Malaria cases in Florida and Texas: Here’s what you need to know

Anavex keeps shifting the goalposts in its clinical trials

hotspot

Vivek Ramaswamy made waves in the debate, much as in biotech

Study: Spinal cord stimulation helps patients with paralysis walk again

Abortion policy in the spotlight at Republican debate

Police still searching for prisoner who escaped from NYC hospital

Trans patients at the end of life deserve respect and dignity

Maui's cultural, historic landmarks damaged in the devastating wildfires

focus

explore

focus

hotspot